US LNG exports surge but will buyers in China turn up?
Neal Pawar, the Chief Operating Officer of Enfusion , Inc. (NYSE:ENFN), recently sold shares of the company’s Class A common stock. According to a filing with the Securities and Exchange Commission, Pawar sold 14,560 shares on March 5, 2025, at a weighted average price of $11.375 per share, totaling approximately $165,620. The transaction comes as the stock trades near its 52-week high of $11.80, having gained nearly 40% over the past six months, according to InvestingPro data.
The shares were sold to cover tax withholding obligations related to the issuance of shares and were not discretionary trades by Pawar. Following this transaction, Pawar retains ownership of 1,217,067 shares in the company. The $1.46 billion market cap company maintains strong financial health, with a current ratio of 3.42 indicating robust liquidity.
The sale was executed in multiple transactions with prices ranging from $11.32 to $11.455 per share. Full details of the transactions are available upon request from the SEC. With revenue growth of 15.5% and several positive indicators, investors can access comprehensive analysis and 11 additional key insights through InvestingPro’s detailed research report.
In other recent news, Enfusion Inc. announced its fourth-quarter earnings for 2024, which were released after market hours. The company is set to be acquired by Clearwater Analytics for $11.25 per share, a development that has significantly influenced analyst ratings. Stifel has downgraded Enfusion’s stock from Buy to Hold, aligning its price target with the acquisition offer at $11.25. This decision reflects the analysts’ view that the acquisition price is fair and likely to stabilize the stock’s value. Morgan Stanley (NYSE:MS) also adjusted its rating, downgrading Enfusion from Overweight to Equal-weight, while increasing the price target to match the acquisition offer. The firm noted that the acquisition could expedite value realization for shareholders, addressing concerns over Enfusion’s market position. Analysts have highlighted that the acquisition price represents a premium over the stock’s prior closing price, indicating Clearwater’s willingness to pay above market valuation. The acquisition agreement is seen as a pivotal moment for Enfusion, with investors closely watching the unfolding developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.